title: ÐÐ¾Ð»ÑÑÐµÐ½Ð¸Ðµ ÑÐµÐºÐ¾Ð¼Ð±Ð¸Ð½Ð°Ð½ÑÐ½Ð¾Ð¹ ÐÐÐ, ÐºÐ¾Ð´Ð¸ÑÑÑÑÐµÐ¹ ÑÐ¸Ð½ÑÐµÐ· Ð¼Ð¾Ð´Ð¸ÑÐ¸ÑÐ¸ÑÐ¾Ð²Ð°Ð½Ð½Ð¾Ð³Ð¾ Ð¸Ð½ÑÑÐ»Ð¸Ð½-Ð¿Ð¾Ð´Ð¾Ð±Ð½Ð¾Ð³Ð¾ ÑÐ°ÐºÑÐ¾ÑÐ° ÑÐ¾ÑÑÐ° (IGF-LR3)
title: Ð²ÑÐ¿ÑÑÐºÐ½Ð°Ñ ÐºÐ²Ð°Ð»Ð¸ÑÐ¸ÐºÐ°ÑÐ¸Ð¾Ð½Ð½Ð°Ñ ÑÐ°Ð±Ð¾ÑÐ° Ð¼Ð°Ð³Ð¸ÑÑÑÐ°
titleType: Subtitle
title: Preparation of recombinant DNA encoding the synthesis of the modified insulin-like growth factor (IGF-LR3)
Creators: name: ÐÐ¸Ð²Ð¸Ð»ÐµÐ², ÐÐ²Ð³ÐµÐ½Ð¸Ð¹
Publisher: name: Ð¡Ð°Ð½ÐºÑ-ÐÐµÑÐµÑÐ±ÑÑÐ³ÑÐºÐ¸Ð¹ Ð¿Ð¾Ð»Ð¸ÑÐµÑÐ½Ð¸ÑÐµÑÐºÐ¸Ð¹ ÑÐ½Ð¸Ð²ÐµÑÑÐ¸ÑÐµÑ ÐÐµÑÑÐ° ÐÐµÐ»Ð¸ÐºÐ¾Ð³Ð¾
Year: 2020
Subjects: ÑÐµÐºÐ¾Ð¼Ð±Ð¸Ð½Ð°Ð½ÑÐ½Ð°Ñ ÐÐÐ
Ð¸Ð½ÑÑÐ»Ð¸Ð½-Ð¿Ð¾Ð´Ð¾Ð±Ð½ÑÐ¹ ÑÐ°ÐºÑÐ¾Ñ ÑÐ¾ÑÑÐ° 1
IGF LR3
Ð³ÐµÐ½Ð½Ð°Ñ ÑÐµÑÐ°Ð¿Ð¸Ñ
recombinant DNA
insulin-like growth faÑtor 1
gene therapy

description: ÐÐ°Ð½Ð½Ð°Ñ ÑÐ°Ð±Ð¾ÑÐ° Ð¿Ð¾ÑÐ²ÑÑÐµÐ½Ð° ÑÐ¾Ð·Ð´Ð°Ð½Ð¸Ñ Ð³ÐµÐ½ÐµÑÐ¸ÑÐµÑÐºÐ¾Ð¹ ÐºÐ¾Ð½ÑÑÑÑÐºÑÐ¸Ð¸, ÑÐºÑÐ¿ÑÐµÑÑÐ¸ÑÑÑÑÐµÐ¹ ÑÐ¸Ð½ÑÐµÐ· IGF-LR3 Ð² ÐºÐ»ÐµÑÐºÐ°Ñ Ð¼Ð»ÐµÐºÐ¾Ð¿Ð¸ÑÐ°ÑÑÐ¸Ñ. ÐÐ°Ð´Ð°ÑÐ¸, ÐºÐ¾ÑÐ¾ÑÑÐµ ÑÐµÑÐ°Ð»Ð¸ÑÑ Ð² ÑÐ¾Ð´Ðµ Ð¸ÑÑÐ»ÐµÐ´Ð¾Ð²Ð°Ð½Ð¸Ñ: 1. ÐÐ¾Ð»ÑÑÐµÐ½Ð¸Ðµ Ð¿Ð»Ð°Ð·Ð¼Ð¸Ð´Ñ, ÑÐºÑÐ¿ÑÐµÑÑÐ¸ÑÑÑÑÐµÐ¹ ÑÐµÐ»ÐµÐ²Ð¾Ð¹ Ð³ÐµÐ½. 2. Ð¡Ð¾Ð·Ð´Ð°Ð½Ð¸Ðµ ÑÐµÐºÐ¾Ð¼Ð±Ð¸Ð½Ð°Ð½ÑÐ½Ð¾Ð³Ð¾ Ð±Ð°ÐºÑÐµÑÐ¸Ð°Ð»ÑÐ½Ð¾Ð³Ð¾ ÑÑÐ°Ð¼Ð¼Ð° Ð´Ð»Ñ Ð½Ð°ÑÐ°Ð±Ð¾ÑÐºÐ¸ Ð¿Ð¾Ð»ÑÑÐµÐ½Ð½Ð¾Ð¹ Ð¿Ð»Ð°Ð·Ð¼Ð¸Ð´Ð½Ð¾Ð¹ ÐºÐ¾Ð½ÑÑÑÑÐºÑÐ¸Ð¸ Ð² Ð¾Ð¿ÑÑÐ½Ð¾-Ð¿ÑÐ¾Ð¼ÑÑÐ»ÐµÐ½Ð½Ð¾Ð¼ Ð¼Ð°ÑÑÑÐ°Ð±Ðµ. 3. ÐÐ¾Ð»ÑÑÐµÐ½Ð¸Ðµ Ð¼Ð¾Ð´ÐµÐ»ÑÐ½Ð¾Ð¹ ÐºÐ»ÐµÑÐ¾ÑÐ½Ð¾Ð¹ ÐºÑÐ»ÑÑÑÑÑ-Ð¿ÑÐ¾Ð´ÑÑÐµÐ½ÑÐ° ÑÐµÐºÐ¾Ð¼Ð±Ð¸Ð½Ð°Ð½ÑÐ½Ð¾Ð³Ð¾ Ð±ÐµÐ»ÐºÐ° IGF-LR3. Ð Ð°Ð±Ð¾ÑÐ° Ð¿ÑÐ¾Ð²ÐµÐ´ÐµÐ½Ð° Ð½Ð° Ð±Ð°Ð·Ðµ Ð¤ÐÐ£Ð ÐÐÐÐ ÐÐ¾ÐµÐ½Ð½Ð¾Ð¹ ÐÐµÐ´Ð¸ÑÐ¸Ð½Ñ ÐÐ Ð Ð¤ Ð¿ÑÐ¸ Ð¿Ð¾Ð´Ð´ÐµÑÐ¶ÐºÐµ ÑÐ¸ÑÐ¼Ñ ÐÐÐ Â«ÐÐÐÐ¡Ð¡ÐÐ¢Â». Ð ÑÐ¾Ð´Ðµ ÑÐºÑÐ¿ÐµÑÐ¸Ð¼ÐµÐ½ÑÐ¾Ð² ÑÐ¾Ð·Ð´Ð°Ð½Ð° Ð¿Ð»Ð°Ð·Ð¼Ð¸Ð´Ð° pcDNA3.1(+)-IGF-LR3, ÐºÐ¾Ð´Ð¸ÑÑÑÑÐ°Ñ ÑÐµÐ»ÐµÐ²Ð¾Ð¹ Ð³ÐµÐ½, Ð° ÑÐ°ÐºÐ¶Ðµ ÑÐµÐºÐ¾Ð¼Ð±Ð¸Ð½Ð°Ð½ÑÐ½ÑÐ¹ ÑÑÐ°Ð¼Ð¼ Escherichia coli DH5Î±/pcDNA3.1(+)-IGF-LR3. ÐÑÐ¾Ð²ÐµÐ´ÐµÐ½Ñ ÑÐºÑÐ¿ÐµÑÐ¸Ð¼ÐµÐ½ÑÑ Ð¿Ð¾ Ð²ÑÐ´ÐµÐ»ÐµÐ½Ð¸Ñ Ð¿Ð»Ð°Ð·Ð¼Ð¸Ð´Ñ pcDNA3.1(+)-IGF-LR3 Ð¸Ð· Ð±Ð°ÐºÑÐµÑÐ¸Ð¹. ÐÐ¾Ð»ÑÑÐµÐ½Ð° ÑÐµÐºÐ¾Ð¼Ð±Ð¸Ð½Ð°Ð½ÑÐ½Ð°Ñ ÐºÑÐ»ÑÑÑÑÐ° ÐºÐ»ÐµÑÐ¾Ðº ÑÐ¸Ð±ÑÐ¾Ð±Ð»Ð°ÑÑÐ¾Ð², Ð½ÐµÑÑÑÐ°Ñ Ð¿Ð»Ð°Ð·Ð¼Ð¸Ð´Ñ pcDNA3.1(+)-IGF-LR3. ÐÐ° ÐºÑÐ»ÑÑÑÑÐµ ÐºÐ»ÐµÑÐ¾Ðº ÑÐ¸Ð±ÑÐ¾Ð±Ð»Ð°ÑÑÐ¾Ð² Ð¿ÑÐ¾Ð´ÐµÐ¼Ð¾Ð½ÑÑÑÐ¸ÑÐ¾Ð²Ð°Ð½Ð° ÑÐºÑÐ¿ÑÐµÑÑÐ¸Ñ ÑÐµÐ»ÐµÐ²Ð¾Ð³Ð¾ Ð³ÐµÐ½Ð° Ñ Ð¿Ð¾Ð»ÑÑÐµÐ½Ð¸ÐµÐ¼ Ð±ÐµÐ»ÐºÐ° IGF-LR3. Ð ÑÐµÐ·ÑÐ»ÑÑÐ°ÑÐµ Ð±ÑÐ»Ð° ÑÐ°Ð·ÑÐ°Ð±Ð¾ÑÐ°Ð½Ð° ÑÐµÑÐ½Ð¾Ð»Ð¾Ð³Ð¸Ñ Ð¿Ð¾Ð»ÑÑÐµÐ½Ð¸Ñ Ð¿Ð»Ð°Ð·Ð¼Ð¸Ð´Ð½Ð¾Ð¹ ÐºÐ¾Ð½ÑÑÑÑÐºÑÐ¸Ñ pcDNA3.1(+)-IGF-LR3 Ð² Ð¾Ð¿ÑÑÐ½Ð¾-Ð¿ÑÐ¾Ð¼ÑÑÐ»ÐµÐ½Ð½Ð¾Ð¼ Ð¼Ð°ÑÑÑÐ°Ð±Ðµ, ÑÑÐ¾ Ð¼Ð¾Ð¶ÐµÑ Ð¿Ð¾ÑÐ»ÑÐ¶Ð¸ÑÑ Ð¾ÑÐ½Ð¾Ð²Ð¾Ð¹ Ð´Ð»Ñ Ð¿ÑÐ¾Ð¼ÑÑÐ»ÐµÐ½Ð½Ð¾Ð¹ ÑÐ°Ð·ÑÐ°Ð±Ð¾ÑÐºÐ¸ Ð³ÐµÐ½Ð¾ÑÐµÑÐ°Ð¿ÐµÐ²ÑÐ¸ÑÐµÑÐºÐ¾Ð³Ð¾ Ð¿ÑÐµÐ¿Ð°ÑÐ°ÑÐ°.
description: This work is devoted to the creation of a genetic construct expressing the IGF-LR3 in mammalian cells. Tasks that were solved during this study: 1. Preparation of plasmid expressing the target gene. 2. Creation of recombinant bacterial strains for pilot scale production of target plasmid construction. 3. Preparation of model cell culture which were producing recombinant protein IGF-LR3. This work was carried out on the basis of the FSUE SRI Military Medicine of the Russian Federation Ministry of Defense with the support of the BIOSSET company. During the experiments, the plasmid pcDNA3.1 (+)-IGF-LR3 that encodes the target gene, as well as the recombinant Escherichia coli strain DH5Î±/pcDNA3.1 (+)-IGF-LR3 was created. The plasmid pcDNA3.1(+)-IGF-LR3 from bacteria was isolated. A recombinant fibroblast cell culture carrying the plasmid was obtained. In a fibroblast cell culture, expression of a target gene to produce IGF-LR3 protein has been demonstrated. As a result, a technology to obtain the plasmid construct pcDNA3.1(+)-IGF-LR3 on a pilot scale was developed, which can serve as the basis for the in-dustrial development of a gene therapy drug.